Repository of Research and Investigative Information

Repository of Research and Investigative Information

Zahedan University of Medical Sciences

Autologous Stem Cell Transplantation with Moderate Dose of Idarubicin and Busulphan as Conditioning Regimen in Acute Myelogenous Leukemia

(2008) Autologous Stem Cell Transplantation with Moderate Dose of Idarubicin and Busulphan as Conditioning Regimen in Acute Myelogenous Leukemia. Iranian Red Crescent Medical Journal. pp. 202-207. ISSN 2074-1804

Full text not available from this repository.

Official URL: <Go to ISI>://WOS:000264127700010

Abstract

Background: Over 50 of patients with AML still relapse after autologous stem cell transplantation. We investigated the efficacy and feasibility of a new conditioning regimen consisting of a moderate dose of idarubicine plus conventional dose of oral busulfan in patients undergoing autologous transplantation without favorable cytogenitic state and high dose therapy with Cytarabine or other drugs. Methods: Ten Patients were given three days of bolus infusion of IDA followed by four days of oral busulfan as conditioning regimen. Unpurged peripheral blood stem cells were used in all cases. All the cases were in first complete remission (CR1). The reasons for the selection of these patients in the first remission were that they had not received high dose chemotherapy or did not have available cytogenitic state. Results: The transplant related mortality occurred in one case (refactory thrombocytopenia, leading to CNS hemorrhage). The median CD34+ cell infused was 8 x 10(6)/kg. The median days to neutrophil recovery > (0.5 x 10 9) and platelet recovery > (20 x 10 (9)/kg) were +9 days (4-12 days); +16 (2-30 days) respectively. The patients needed transfusion of a median of 15 platelet units and 7 blood units, respectively. Six out of 10 patients (60) had variable grades of mucositis (three cases had grade III, two grade II and one case grade I). After a median follow up of 48 months from ASCT, 8 patients out of 10 (80) were alive in continuous complete remission. One case had relapse after 6 months of transplantation. Conclusion: The findings of the study demonstrated the efficacy and feasibility of a conditioning regimen based on a moderate dose of IDA plus busulphan in AML. The results concerning anti-leukemic efficacy are promising but need to be confirmed on larger series.

Item Type: Article
Keywords: Acute myeloid leukemia Stem cell transplantation Idarubicin Busulphan bone-marrow-transplantation acute myeloid-leukemia acute nonlymphocytic leukemia 1st remission consolidation chemotherapy intensive chemotherapy follow-up adults trial immunotherapy General & Internal Medicine
Page Range: pp. 202-207
Journal or Publication Title: Iranian Red Crescent Medical Journal
Journal Index: ISI
Volume: 10
Number: 3
ISSN: 2074-1804
Depositing User: خانم مهدیه رضائی پور
URI: http://eprints.zaums.ac.ir/id/eprint/2847

Actions (login required)

View Item View Item